Newsroom
Sorted by: Latest
-
Robbins LLP Urges ZoomInfo Technologies Inc. Stockholders to Contact the Firm for Information About the Class Action Against GTM
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ZoomInfo Technologies Inc. (NASDAQ: GTM) securities between November 3, 2025 and May 11, 2026. ZoomInfo Technologies Inc., together with its subsidiaries, provides go-to-market intelligence and engagement platform for sales, marketing, operations, and recruiting professionals in the United States and internationally.For more information, submit...
-
BRAIN Foundation Launches Aurora Research Network to Transform Care for Youth with Severe Neuropsychiatric Disorders
PLEASANTON, Calif.--(BUSINESS WIRE)--In collaboration with Stanford Medicine, The BRAIN Foundation launched the Aurora Research Network, backing the effort with an initial $2M pledge....
-
American Beacon Partners Appoints William MacGregor as Deputy General Counsel
IRVING, Texas--(BUSINESS WIRE)--American Beacon today announced the appointment of William (“Bill”) MacGregor as Deputy General Counsel....
-
معرض SIAL Paris 2026: الحدث الذي يسلّط الضوء على صناعة الأغذية الزراعية العالمية ويسرّع وتيرة تطورها
باريس--(BUSINESS WIRE)--قبل بضعة أشهر من انطلاق SIAL Paris 2026 (في الفترة من 17 إلى 21 أكتوبر، في Paris Nord Villepinte)، أماط المعرض التجاري اللثام عن نتائج تقريره الجديد SIAL Insights 2026، وهو تحليل دولي يحدد عشرة اتجاهات رئيسية من المتوقع أن تُحدث تغييرات دائمة تطول أسواق الأغذية وسلوك المستهلكين.أُعدّ التقرير بالاعتماد على بيانات حصرية من Kantar Food 360™ وCircana وProtéinesXTC، ويسلّط الضوء على منهج تجريبي قوامه التخصيص والفعالية في مجال الأغذية، كما يكشف عن المفاضلات الجديدة التي يجريها...
-
NUBURU Advances on Tekne Acquisition, Extinguishing $16.75 Million in Debt Days After $38.0 Million Offering
DENVER--(BUSINESS WIRE)--NUBURU, Inc. (OTC Pink: BURU), a next-generation dual-use Defense & Security integrated platform company, today announced it has repaid in full the approximately $15.5 million remaining principal of its December 2025 debenture and the entire $1.25 million aggregate principal of the subordinated convertible notes issued in connection with its acquisition of Lyocon S.r.l. ("Lyocon") — approximately $16.75 million of principal obligations extinguished within days of cl...
-
Harlow Payments Appoints Industry Veteran Ray Sidhom as Executive Chairman
[NEW YORK--(BUSINESS WIRE)--Harlow Payments, the premier payments processing solution helping businesses simplify financial operations, today announced the appointment of payments industry veteran Ray Sidhom as Executive Chairman. As Executive Chairman, Sidhom will work alongside Harlow's leadership team to help guide the company's long-term strategy and continued growth as it expands its suite of offerings and partnerships. "Ray's track record speaks for itself, and we’re thrilled to have him...
-
Avenue Growth Partners Announces the Close of Its Second Fund at Hard Cap
WASHINGTON--(BUSINESS WIRE)--Avenue Growth Partners (“Avenue”), an early growth equity firm backing category-defining vertical technology companies, today announced the close of its second fund, Avenue Growth Partners Fund II, at $155 million. The fund, which follows Avenue’s $83 million debut fund, was significantly oversubscribed and closed at its hard cap. Fund II has attracted a diverse base of institutional capital, with limited partners spanning public pensions, private foundations, funds...
-
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
FOSTER CITY, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacap...
-
Gilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janeiro, Brazil, from July 26-31. As a leader in HIV innovation, Gilead will share new scientific data from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. The data to be presented, together with Gilead-led symposia and community forums,...
-
Parafin Closes $300 Million Forward-Flow Deal with NY-Based Alternative Asset Manager
SAN FRANCISCO--(BUSINESS WIRE)--Parafin, the leading embedded financial infrastructure company, today announced a new forward-flow agreement backed by a top New York-based alternative asset manager. Under this forward-flow agreement, up to $300 million of loans would be originated through Parafin's platform and purchased into a rated vehicle.Building on recently announced partnerships with Goldman Sachs and EverBank, along with renewed commitment from First Citizens, this agreement expands Paraf...